In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system

Journal of Immunology

Volumn 170, Issue 3, 2003, Pages 1274-1282

  Denkinger, Claudia M ^a,c   Denkinger, Michael ^a   Kort, Jens J ^a,b   Metz, Christine ^d   Forsthuber, Thomas G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; EFFECTOR CELL; LYMPHOCYTE HOMING; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0037307824     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.3.1274     Document Type: Article

References (54)

1. Rivers, T. M., and F. F. Schwentker. 1935. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J. Exp. Med. 61:689.
2. Steinman, L. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299.
3. b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur. J. Immunol. 25:1951.
4. 1 integrin. Nature 356:63.
5. Karpus, W. J., N. W. Lukacs, B. L. McRae, R. M. Strieter, S. L. Kunkel, and S. D. Miller. 1995. An important role for the chemokine macrophage inflammatory protein-1α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155:5003.
6. Glabinski, A. R., S. O'Bryant, K. Selmaj, and R. M. Ransohoff. 2000. CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 917:135.
7. David, J. R. 1966. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA 56:72.
8. Bloom, B. R., and B. Bennett. 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80.
9. Calandra, T., J. Bernhagen, R. A. Mitchell, and R. Bucala. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179:1895.
10. Nishino, T., J. Bernhagen, H. Shiiki, T. Calandra, K. Dohi, and R. Bucala. 1995. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol. Med. 1:781.
11. Weiser, W. Y., P. A. Temple, J. S. Witek-Giannotti, H. G. Remold, S. C. Clark, and J. R. David. 1989. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA 86:7522.
12. Bernhagen, J., R. A. Mitchell, T. Calandra, W. Voelter, A. Cerami, and R. Bucala. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33:14144.
13. Bacher, M., C. N. Metz, T. Calandra, K. Mayer, J. Chesney, M. Lohoff, D. Gemsa, T. Donnelly, and R. Bucala. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA 93:7849.
14. Mikulowska, A., C. N. Metz, R. Bucala, and R. Holmdahl. 1997. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J. Immunol. 158:5514.
15. Lan, H. Y., N. Yang, C. Metz, W. Mu, Q. Song, D. J. Nikolic-Paterson, M. Bacher, R. Bucala, and R. C. Atkins. 1997. TNF-α up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol. Med. 3:136.
16. Mizue, Y., J. Nishihira, T. Miyazaki, S. Fujiwara, M. Chida, K. Nakamura, K. Kikuchi, and M. Mukai. 2000. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int. J. Mol. Med. 5:397.
17. Niino, M., A. Ogata, S. Kikuchi, K. Tashiro, and J. Nishihira. 2000. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J. Neurol. Sci. 179:127.
18. Bacher, M., A. Meinhardt, H. Y. Lan, F. S. Dhabhar, W. Mu, C. N. Metz, J. A. Chesney, D. Gemsa, T. Donnelly, R. C. Atkins, and R. Bucala. 1998. MIF expression in the rat brain: implications for neuronal function. Mol. Med. 4:217.
19. Galat, A., S. Riviere, F. Bouet, and A. Menez. 1994. A diversified family of 12-kDa proteins with a high amino acid sequence similarity to macrophage migration-inhibitory factor (MIF). Eur. J. Biochem. 224:417.
20. Chesney, J., C. Metz, M. Bacher, T. Peng, A. Meinhardt, and R. Bucala. 1999. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5:181.
21. Rocken, M., M. Racke, and E. M. Shevach. 1996. IL-4 induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 17:225.
22. Lehmann, P. V., T. Forsthuber, A. Miller, and E. E. Sercarz. 1992. Spreading of T-eell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155.
23. Shive, C. L., H. Hofstetter, L. Arredondo, C. Shaw, and T. G. Forsthuber. 2000. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur. J. Immunol. 30:2422.
24. Karulin, A. Y., M. D. Hesse, M. Tary-Lehmann, and P. V. Lehmann. 2000. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J. Immunol. 164:1862.
25. Yip, H. C., A. Y. Karulin, M. Tary-Lehmann, M. D. Hesse, H. Radeke, P. S. Heeger, R. P. Trezza, F. P. Heinzel, T. Forsthuber, and P. V. Lehmann. 1999. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162:3942.
26. Racke, M. K., S. Dhib-Jalbut, B. Cannella, P. S. Albert, C. S. Raine, and D. E. McFarlin. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146:3012.
27. Kort, J. J. 1998. Impairment of excitatory amino acid transport in astroglial cells infected with the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:1329.
28. Kaifi, J. T., E. Diaconu, and E. Pearlman. 2001. Distinct roles for PECAM-1, ICAM-1, and VCAM-1 in recruitment of neutrophils and eosinophils to the cornea in ocular onchocerciasis (river blindness). J. Immunol. 166:6795.
29. Greenwood, J., Y. Wang, and V. L. Calder. 1995. Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1: off. Immunology 86:408.
30. Steffen, B. J., E. C. Butcher, and B. Engelhardt. 1994. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am. J. Pathol. 145:189.
31. 4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA 96:6896.
32. Hori, J., M. Isobe, S. Yamagami, and T. Tsuru. 1998. Acceptance of second corneal allograft by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Transplant. Proc. 30:200.
33. Irani, D. N., and D. E. Griffin. 1996. Regulation of lymphocyte homing into the brain during viral encephalitis at various stages of infection. J. Immunol. 156:3850.
34. Qing, Z., M. Sandor, Z. Radvany, D. Sewell, A. Falus, D. Potthoff, W. A. Muller, and Z. Fabry. 2001. Inhibition of antigen-specific T cell trafficking into the central nervous system via blocking PECAM1/CD31 molecule. J. Neuropathol. Exp. Neurol. 60:798.
35. Carrithers, M. D., I. Visintin, S. J. Kang, and C. A. Janeway, Jr. 2000. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123:1092.
36. Lan, H. Y., M. Bacher, N. Yang, W. Mu, D. J. Nikotic-Paterson, C. Metz, A. Meinhardt, R. Bucala, and R. C. Atkins. 1997. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J. Exp. Med. 185:1455.
37. Theien, B. E., C. L. Vanderlugt, T. N. Eagar, C. Nickerson-Nutter, R. Nazareno, V. K. Kuchroo, and S. D. Miller. 2001. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107:995.
38. Wildbaum, G., N. Netzer, and N. Karin. 2002. Plasmid DNA encoding IFN-γ-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 168:5885.
39. + T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 166:7617.
40. Karpus, W. J., and K. J. Kennedy. 1997. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukocyte Biol. 62:681.
41. Kennedy, K. J., R. M. Strieter, S. L. Kunkel, N. W. Lukacs, and W. J. Karpus. 1998. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1. J. Neuroimmunol. 92:98.
42. Dufour, J. H., M. Dziejman, M. T. Liu, J. H. Leung, T. E. Lane, and A. D. Luster. 2002. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168:3195.
43. Murakami, H., S. M. Akbar, H. Matsui, N. Horiike, and M. Onji. 2002. Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin. Exp. Immunol. 128:504.
44. Hermanowski-Vosatka, A., S. S. Mundt, J. M. Ayala, S. Goyal, W. A. Hanlon, R. M. Czerwinski, S. D. Wright, and C. P. Whitman. 1999. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 38:12841.
45. 1 integrin and TCR rescues human thymocytes from steroid-induced apoptosis. Int. Immunol. 10:1551.
46. Targoni, O. S., and P. V. Lehmann. 1998. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J. Exp. Med. 187:2055.
47. Radvanyi, L. G., Y. Shi, H. Vaziri, A. Sharma, R. Dhala, G. B. Mills, and R. G. Miller. 1996. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J. Immunol. 156:1788.
48. Collette, Y., D. Razanajaona, M. Ghiotto, and D. Olive. 1997. CD28 can promote T cell survival through a phosphatidylinositol 3-kinase-independent mechanism. Eur. J. Immunol. 27:3283.
49. Walker, L. S., J. D. McLeod, G. Boulougouris, Y. I. Patel, N. D. Hall, and D. M. Sansom. 1998. Down-regulation of CD28 via Fas (CD95): influence of CD28 on T-cell apoptosis. Immunology 94:41.
50. + T lymphocytes. Proc. Natl. Acad. Sci. USA 88:6403.
51. Damle, N. K., K. Klussman, G. Leytze, H. D. Ochs, A. Aruffo, P. S. Linsley, and J. A. Ledbetter. 1993. Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell. Immunol. 148:144.
52. Maloy, K. J., and F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816.
53. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
54. Miller, A., O. Lider, A. B. Roberts, M. B. Sporn, and H. L. Weiner. 1992. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor-β after antigen-specific triggering. Proc. Natl. Acad. Sci. USA 89:421.